A Herpesviral Lytic Protein Regulates the Structure of Latent Viral Chromatin

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

Citation
Raja, Priya, Jennifer S. Lee, Dongli Pan, Jean M. Pesola, Donald M. Coen, and David M. Knipe. 2016. “A Herpesviral Lytic Protein Regulates the Structure of Latent Viral Chromatin.” mBio 7 (3): e00633-16. doi:10.1128/mBio.00633-16. http://dx.doi.org/10.1128/mBio.00633-16.

Published Version
doi:10.1128/mBio.00633-16

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:27662041

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
A Herpesviral Lytic Protein Regulates the Structure of Latent Viral Chromatin

Priya Raja,a Jennifer S. Lee,a,b Dongli Pan,c* Jean M. Pesola,c Donald M. Coen,b,c David M. Knipea,b

Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USAa; Program in Virology, Harvard Medical School, Boston, Massachusetts, USAa; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USAa

* Present address: Dongli Pan, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
P.R. and J.S.L. contributed equally to this work.

ABSTRACT Latent infections by viruses usually involve minimizing viral protein expression so that the host immune system cannot recognize the infected cell through the viral peptides presented on its cell surface. Herpes simplex virus (HSV), for example, is thought to express noncoding RNAs such as latency-associated transcripts (LATs) and microRNAs (miRNAs) as the only abundant viral gene products during latent infection. Here we describe analysis of HSV-1 mutant viruses, providing strong genetic evidence that HSV-infected cell protein 0 (ICP0) is expressed during establishment and/or maintenance of latent infection in murine sensory neurons in vivo. Studies of an ICP0 nonsense mutant virus showed that ICP0 promotes heterochromatin and latent and lytic transcription, arguing that ICP0 is expressed and functional. We propose that ICP0 promotes transcription of LATs during establishment or maintenance of HSV latent infection, much as it promotes lytic gene transcription. This report introduces the new concept that a lytic viral protein can be expressed during latent infection and can serve dual roles to regulate viral chromatin to optimize latent infection in addition to its role in epigenetic regulation during lytic infection. An additional implication of the results is that ICP0 might serve as a target for an antiviral therapeutic acting on lytic and latent infections.

IMPORTANCE Latent infection by viruses usually involves minimizing viral protein synthesis so that the host immune system cannot recognize the infected cells and eliminate them. Herpes simplex virus has been thought to express only noncoding RNAs as abundant gene products during latency. In this study, we found genetic evidence that an HSV lytic protein is functional during latent infection, and this protein may provide a new target for antivirals that target both lytic and latent infections.

The herpesviruses are characterized by the ability to establish a latent infection, in which no infectious virus is found, following an acute infection in the host organism (1). Herpes simplex virus (HSV) initially productively infects epithelial tissue (“lytic” infection), from which it spreads to establish a latent infection in sensory neurons (2). HSV directly causes significant morbidity and mortality; moreover, it promotes HIV infection (2). The existing antiviral therapies target lytic infection; thus, therapeutic strategies to cure latent infections will require new antiviral strategies. Additional knowledge about the mechanisms of HSV latent infection is needed to design therapeutics that target latent infection.

HSV lytic and latent infections have been thought to occur along distinct pathways and to be driven by different viral gene products (2, 3). The HSV DNA genome is packaged in virions without associated histones, but during lytic infection, the HSV genome enters the host cell nucleus and is rapidly associated with heterochromatin, which is then modified to euchromatin (4–6). Virion protein 16 (VP16) assembles into a complex with host proteins, and the complex recruits chromatin-remodeling and histone-modifying proteins to viral immediate-early (IE) promoters to reduce total histone and heterochromatin occupancy and to increase euchromatin marks on IE genes (7). One of the resulting IE proteins, infected cell protein 0 (ICP0), reduces total histone loading and heterochromatin and increases euchromatin on the rest of the genome (5, 6). Known mechanisms of ICP0 action in promoting gene expression include inactivation of repressive effects of PML/Sp100/Daxx/ATRX (8–11), disruption of the CoREST-histone deacetylase (HDAC) complex (12), recruitment of the CLOCK histone acetyltransferase (13), and degradation of IFI16 (14).

In contrast to lytic infection, where the HSV genome is rapidly heterochromatinized within 1 to 2 h of infection, the HSV-1 latent genome accumulates histones gradually over days and weeks following infection (15, 16). Previous experiments in the mouse ocular infection model indicate that histone H3 association with viral genomes in trigeminal ganglia (TG) takes up to 7 days postinfection (dpi), whereas H3K27me3 association was not detectable until 10 to 14 dpi (15).
During latent infection of mice, HSV-1 does not produce infectious virus, and although many viral genes are expressed, their expression levels are rather low, with the only abundant viral transcripts accumulating from the latency-associated transcript (LAT) region (17–23). The HSV latent genome is organized in ordered nucleosomes (24), and the silencing of viral genes during latent infection correlates with the accumulation of histones and heterochromatin modifications during the establishment of latency (16). Viral lytic promoters are associated with chromatin characterized by constitutive H3K9me3 and facultative H3K27me3 heterochromatin modifications, while the LAT promoter is associated with bivalent chromatin characterized by both euchromatin and heterochromatin modifications, without any role for DNA methylation (15, 16, 25–27). This has led to the hypothesis that an epigenetic switch initiates the transition of the viral genome from lytic to latent infection.

The LATs play several potential roles in promoting latent infection in that they have been implicated in promoting cell survival by inhibiting apoptosis or other mechanisms of cell death (28, 29), repressing lytic gene expression (30, 31), and facilitating heterochromatin accumulation on the viral genome (16, 25). Enrichment of H3K27me3 is promoted by LATs in our system and corresponds to a significant accumulation of the PRC2 component Suz12 on lytic promoters by 14 dpi but not the PRC1 component Bmi1 (15, 25, 26). Interestingly, recruitment of Suz12 occurs independently of LAT transcription, suggesting that additional viral mechanisms promote H3K27me3 accumulation (15). Whereas heterochromatin modifications were previously believed to represent a terminally silenced genome, it has become increasingly clear that latent infection is not characterized by permanent and static repression of the viral genome but represents an ongoing dynamic balance mediated by both the virus and the infected cell (17, 18, 32, 33).

The lytic and latent infection pathways have been thought to be distinct and involve separate viral gene products. Several important functions have been described for the IE ICP0 protein during lytic infection. ICP0 promotes viral lytic replication at low multiplicities of infection (MOIs) and to different extents in different cell types (34). This involves ICP0 promoting reversal of host cell epigenetic silencing of the viral genome (6) and inhibition of host restriction mechanisms, as described above. ICP0 has been shown to promote viral reactivation (35–38), but this was thought to be due to its functions in promoting lytic infection.

Interestingly, there is evidence that, in latent infection, low levels of ICP0 and other lytic transcripts are detectable in the absence of reactivation (17, 20, 39–42). Furthermore, there is evidence that the ICP0 gene promoter is active at some point during the establishment of latency in at least one-third of latently infected neurons (41). Also, recently, a mutation that results in increased expression of ICP0 in neurons was shown to lead to increased expression of lytic genes in ganglia during establishment and maintenance of latency (33).

One study involving infection of sensory neurons in vitro resulted in a report that ICP0 is necessary for efficient establishment of latent infection (43). However, those were in vitro experiments involving incubation of neurons with the antiviral drug acyclovir during infection. We therefore examined the potential role of ICP0 in latent infection in vivo in a mouse infection model. In contrast to lytic infection results, we found that ICP0 promoted both LAT and lytic gene expression in latently infected ganglia as well as total histone and heterochromatin loading on the latent HSV genome. This new function of ICP0 raises the potential of antivirals targeting it for use as therapeutics for HSV latent infection.

RESULTS

ICP0-null mutant viruses show reduced replication in mouse ocular infection. We wished to test the role of the HSV-1 ICP0 protein in latent infection, and previous studies had utilized an HSV-1 mutant virus (7134) with a lacZ insertion in the ICP0 gene (44). This virus shows altered LAT expression (36; our unpublished results), which complicates interpretation of the results. Other studies had compared the HSV-1 n212 ICP0 nonsense mutant virus to wild-type (WT) virus but did not analyze a rescued virus (38) (Fig. 1). The n212 mutant virus has minimal changes in the LAT coding sequences; therefore, we utilized the HSV-1 n212 ICP0 nonsense mutant and constructed a rescued n212R virus. We also constructed the HSV-1 dProm ICP0 promoter deletion mutant virus and generated the PromR rescued virus, as described previously (6). The n212R and PromR rescued viruses were shown
HSV-1 ICP0 Regulates Latent Viral Chromatin

Previously to have replication kinetics and gene expression and chromatin profiles similar to those of WT KOS virus in acute infection (6). Previous studies had shown that ICP0-negative (ICP0−) viruses show reduced ocular replication, so higher doses of the mutant viruses were needed to establish comparable levels of latent infection (38, 45). To determine the relative doses of ICP0− and ICP0+ viruses that gave equivalent titers in the eye at peak times of replication (2 to 3 dpi), we infected mice with various doses of the viruses by the corneal route, collected eye swabs daily up to 5 dpi, and titrated the virus in the tear fluid on U2OS cells, which complement the growth of ICP0 mutant viruses (46), to assess acute replication in the eye. We observed viral titers at 2 dpi in mice infected with $2 \times 10^4$ PFU/eye of the ICP0 mutant virus dProm or n212 that were equivalent to those seen with mice infected with $2 \times 10^4$ PFU/eye of the PromR or n212R rescued viruses, but then the ICP0+ virus titers increased to levels above the ICP0− virus titers, with statistically significant differences by 4 to 5 dpi ($P < 0.05$) (Fig. 2A and B). All of the ICP0− virus-infected animals survived, but reduced numbers of ICP0+ virus-infected animals survived, which was significant for the comparison of n212 results to n212R results ($P < 0.001$) (Fig. 2C and D). These results were consistent with increased replication of ICP0+ viruses in ganglia, increased lethality, and increased spread of virus from the ganglia back to the cornea. These inocula were used for all subsequent experiments because they gave equivalent peak viral titers in the eye.

**Total chromatin and heterochromatin profiles on lytic and latent gene sequences in genomes of ICP0− and ICP0+ viruses.**

To measure the effects of ICP0 on chromatin association with latent viral genomes, we evaluated the total chromatin and heterochromatin profiles on HSV-1 latent genomes from ICP0− and ICP0+ viruses during latent infection. Mice were sacrificed at 28 dpi, and trigeminal ganglia were harvested. Chromatin immunoprecipitation (ChIP) analysis was performed to measure the association of histone H3, H3K9me3, and H3K27me3 with the viral ICP8 promoter, ICP27 promoter, or LAT promoter (LAT) or the LAT enhancer (E; 5′ exon) relative to cellular GAPDH (glyceraldehyde-3-phosphate dehydrogenase) by quantitative PCR (qPCR) (Fig. 3).

We found approximately equal amounts of viral DNA in chromatin preparations recovered from ganglia infected with mutant viruses and those infected with rescued viruses. We also found that, in general, all the sequences assayed on the latent viral genomes were associated with heterochromatin markers of silencing such as H3K27me3 and H3K9me3, as observed previously (16, 25). However, in contrast to the effect of ICP0 on chromatin during lytic infection (6), we found increased levels of total histones and heterochromatin on the ICP0− viruses relative to the ICP0+ viruses (Fig. 3, panels A to F). In particular, there was a significant increase in H3K27me3 levels on the LAT promoter, or the LAT enhancer (E; 5′ exon) relative to cellular GAPDH (glyceraldehyde-3-phosphate dehydrogenase) by quantitative PCR (qPCR) (Fig. 3).

The trends of H3K9me3 modification were similar to those seen with the H3K27me3 modification but were not statistically significant. The two ICP0− mutant virus strains, n212 and dProm, showed similar phenotypes, arguing that ICP0 promotes increased heterochromatin modifications, in particular, the H3K27me3 modification, at lytic promoters and on the LAT promoter during latent infection.

To examine the latent viral chromatin using an antibody-independent method of chromatin analysis, we used the...
formaldehyde-assisted isolation of regulatory elements (FAIRE) method (47) to measure the ratio of nucleosome-free DNA to nucleosome-bound DNA in the ICP0/H11002 viruses relative to the ICP0/H11001 viruses. This technique uses phenol extraction to recover nucleosome-free DNA in the aqueous phase. We observed increased amounts of nucleosome-free DNA from the ICP0/H11002 viruses relative to the ICP0/H11001 viruses at both the ICP8 promoter and LAP regions (Fig. 4). Although the differences did not reach statistical significance (P < 0.09 for the ICP8 promoter on dProm compared to PromR), the FAIRE results supported our results from ChIP experiments and argued that, in latency, ICP0-expressing viruses were associated with greater levels of repressed and nucleosome-bound chromatin.

**Viral RNA expression during latent infection with ICP0− and ICP0+ viruses.** To determine whether the levels of latent infection transcripts were altered with an ICP0− virus relative to its ICP0+ rescued partner, we performed quantitative reverse transcription PCR (qRT-PCR) to quantify LAT and lytic transcripts in
n212 and n212R latently infected trigeminal ganglia. Viral transcripts measured with primers specific to the LAT intron and to lytic transcripts were normalized to a cellular control. Viral genomes from the same ganglia were measured by qPCR and normalized to cellular DNA. Ganglia from mice infected with n212R virus expressed significantly (14-fold) higher levels of the stable LAT intron than ganglia from those infected with n212 virus ($P < 0.001$) (Fig. 5A). The total amount of viral DNA isolated was also significantly higher in ganglia latently infected with the ICP0 virus than in ganglia latently infected with the ICP0− virus (Fig. 5B). Nevertheless, LAT expression per viral genome was significantly (3.6-fold) higher in ganglia infected with the ICP0+ virus than in ganglia infected with the ICP0− virus at day 28 (Fig. 5C).

We also assayed for lytic viral transcripts from the ICP0, ICP27 (immediate-early), thymidine kinase (tk) (early), and glycoprotein C (gC) (late) genes. As expected, especially given the low inoculating dose of the ICP0+ virus, the levels of these lytic gene transcripts were very low. Because the transcript levels were low, we initially scored ganglia as positive or negative for detectable transcripts. About one-third of ganglia from mice infected with the n212R ICP0+ virus showed detectable ICP0 expression, while only 1/10 of ganglia infected with n212 mutant virus did, which was a significantly smaller proportion (Fisher’s exact test; Table 1). Similarly, a larger proportion of ganglia infected with the n212R ICP0+ virus showed detectable ICP27, tk, and gC gene transcripts, and these differences were significant for the tk and gC gene transcripts (Table 1). When the ganglia were analyzed for numbers of lytic transcripts per genome, there were significantly higher levels of all four lytic transcripts found in ganglia from mice infected with the n212R ICP0+ virus than in ganglia from mice infected with the n212 mutant virus (Mann-Whitney test; Table 1). In total, these results showed that ICP0 promotes increases in levels of both LAT and lytic transcripts.

In summary, during latent infection of neurons, ICP0+ viruses showed increased heterochromatin association on the viral genome, particularly in the case of H3K27me3, and increased LAT and lytic transcript expression relative to ICP0− viruses.

**DISCUSSION**

HSV-1 ICP0 promotes viral lytic replication by promoting viral gene expression and inhibiting host restriction and innate immune mechanisms. The promotion of viral gene expression involves the reversal of the cellular epigenetic silencing of the viral genome through the degradation of the PML, Sp100, Daxx, ATRX, and IFI16 proteins, the disruption of the CoREST-HDAC

---

**FIG 4** FAIRE profile of latent ICP0-expressing and ICP0 mutant genomes. Chromatin from latently infected trigeminal ganglia was evaluated by FAIRE to compare the proportion of nucleosome-free viral DNA relative to the total input viral DNA amount in ICP0-expressing (PromR or n212R) and ICP0 mutant (dProm or n212) viruses. FAIRE results are presented for ICP8 (A) and LAP (B) regions.

**FIG 5** LAT expression in the n212 virus relative to the n212R virus. LAT transcripts were quantified in latently infected trigeminal ganglia by qRT-PCR. Viral transcripts were measured with primers specific to the LAT intron and normalized relative to a cellular control. Viral genomes from the same ganglia were measured by qPCR and normalized to cellular DNA. Statistical significance was evaluated using the Mann-Whitney test. (A) LAT transcripts/TG ($P < 0.0001$). (B) Viral genomes in latently infected trigeminal ganglia ($P < 0.0001$). (C) LAT transcripts/genome ($P < 0.0001$).
TABLE 1 Expression of viral lytic transcripts during latent infection

| Virus (parameter) | Parameter value for indicated gene |
|-------------------|------------------------------------|
| n212 (+/total)a   | ICP0 /total, number of RNA-positive ganglia/total number of ganglia assayed. Ganglia were scored as RNA positive for the indicated gene as described in Materials and Methods. |
| n212R (+/total)   | ICP027/total |
| n212 (RNA/genome)b | tk/total |
| n212R (RNA/genome)| gC/total |
| P valuec          | 0.023 0.110 0.032 0.020 |
| n212 (RNA/genome)d  | 0.0042 0.0045 0.023 0.024 |
| n212R (RNA/genome)| 0.0042 0.0055 0.0026 0.0043 |

a +/total, number of RNA-positive ganglia/total number of ganglia assayed. Ganglia were scored as RNA positive for the indicated gene as described in Materials and Methods.
b The Fisher’s exact test was used to analyze the fraction of TG with detectable expression of viral lytic transcripts during latent infection in n212 versus n212R samples. TG with undetectable genomes were eliminated in this analysis.
c Data represent geometric means of numbers of RNA copies for the indicated genes per viral genome per TG.
d The Mann-Whitney test was used to analyze log (RNA copies-genome).

complexes (8–14), and likely other mechanisms currently unknown. This results in increased transcription of all classes of lytic genes (36). Therefore, it has been believed that ICP0 expression would be counter to epigenetic mechanisms thought to silence gene expression during latent infection. Previous studies showed ICP0 promoter activation in approximately one-third of latently infected neurons prior to the establishment of latency, VP16-independent ICP0 promoter activation, and low levels of ICP0 expression during latency (39–41, 48). We also observed low but detectable levels of ICP0 expression during latency in at least some ganglia, in agreement with previous results. ICP0 has been known to promote establishment of and reacivation from latent infection (37, 38), but this was believed to be due to its effects on lytic infection during acute infection at peripheral sites or during reacivation. Although one publication had argued that ICP0 increased latent infection, that was in an in vitro neuronal infection model that included the use of the antiviral drug acyclovir to prevent viral replication in the cultures (43). However, cell culture models of quiescent HSV-1 infection found that ICP0 expression induced active lytic gene expression and enrichment of acetylated histones while preventing or reducing association of histone H3, H3K9me3, and HP1γ (49–51).

We were therefore surprised to observe that ICP0− viruses showed reduced levels of H3K27me3 and H3K9me3 modified viral chromatin, which is generally considered to indicate the presence of heterochromatin. This phenotype was observed with two different types of ICP0 gene mutants, a nonsense mutant and a promoter mutant. This argues that the phenotype is truly due to the absence of the ICP0 protein. We additionally found that an ICP0 nonsense mutation resulted not only in a decrease in lytic gene expression but also, surprisingly, in a decrease in LAT expression. We therefore propose the following heuristic model (Fig. 6), which warrants further testing. In epithelial cells, ICP0 promotes the reversal of epigenetic silencing by allowing viral ICP4 to activate transcription of viral lytic promoters. In contrast, limited and/or intermittent expression of ICP0 in sensory neurons opens the chromatin sufficiently to increase transcription from not only the one highly active LAT promoter but also the weakly active lytic gene promoters. LAT then increases heterochromatin modifications, in particular, modification of H3K27me3. Each of these steps is discussed in depth below. It is also conceivable that ICP0 promotes the spread of HSV to different neuronal subtypes that load more chromatin and heterochromatin on the viral genome. However, in the absence of additional data supporting this, we favor the simpler model illustrated in Fig. 6.

ICP0 and LAT transcription. We propose that an early effect of ICP0 in sensory neurons is increased LAT transcription. ICP0 has the ability to promote transcription on transfected plasmids (52–55) and open chromatin on transfected plasmids (6) and to promote transcription (34, 36) and euchromatin formation (5) on the HSV genome in infected cells while having little effect on the cellular chromatin (56). Therefore, ICP0 may keep the chromatin open on all viral promoters, allowing resident transcription factors to function. It is well documented that in epithelial cells, ICP0

![Figure 6](https://example.com/figure6.png)
opens chromatin on lytic viral promoters, allowing activation by ICP4 and associated factors (2). In neurons, a region of open chromatin is maintained at the LAT promoter, which contains a variety of binding sites for transcription factors that are present in neurons (57). ICP0 may also at least transiently act on lytic promoters to induce an open or poised form in neurons so that the low level of relevant transcription factors can promote limited transcription of these genes. However, ICP0 induces only a small subset of cellular genes (56), and the basis for ICP0 specifically transcribing these genes remains to be defined. Nonetheless, our results indicate that ICP0 can act on the HSV genome in sensory neurons during acute and/or latent infection to promote LAT and lytic gene transcription.

ICP0 and heterochromatin in neurons. We propose that the increase in heterochromatin levels in neurons as a result of ICP0 expression in ICP0+ virus-infected ganglia is an indirect effect of increased LAT transcription (Fig. 6). As shown previously, latent HSV-1 is associated with heterochromatin. However, we found that ICP0+ viral genomes are associated with increased levels of H3K27me3 and H3K9me3 heterochromatin at lytic gene promoters compared to those seen with ICP0− viral genomes. The increased heterochromatin levels detected by ChIP were consistent with the increased proportion of nucleosome-bound DNA shown by FAIRE analysis, indicating a role for ICP0 in increased chromatin silencing during latent infection.

Interestingly, the significant increase in the level of H3K27me3 heterochromatin at the LAT promoter, LAP, did not appear to correlate with a reduction in LAT transcript accumulation by ICP0-expressing viruses. Similarly, it did not correlate with decreased expression of lytic transcripts. Instead, absolute levels of LAT were higher for the rescued viruses than for the mutant, suggesting that ICP0 may have a role in LAT regulation. LAT has previously been shown to increase H3K27me3 levels on viral lytic promoters (25). LAP has previously been shown to contain both repressive H3K27me3 and activating H3K4me3 modifications during latency, suggesting that H3K27me3 alone might not repress transcription at LAT (25). Bivalent cellular chromatin has been associated with poised transcription (58, 59), and bivalent modifications at the LAT promoter may be an important regulatory mechanism for LAT transcription. The apparent bivalency may also be due to distinct populations of genomes or distinct copies of LAT exhibiting variable chromatin association. LAT expression may be related to localization of viral genomes in proximity to cellular heterochromatin within neuronal cells (60). Advances in single-cell and single-molecule analysis of chromatin and gene expression should enable the resolution of these possibilities.

The increased heterochromatin levels associated with ICP0+ viruses could also indicate that ICP0 modulates chromatin in a cell type- or context-dependent manner. Our recent study identified specific demethylases and chromatin-modifying factors that operate on the ICP8 promoter in a cell type-specific manner (61). Models for the mechanisms by which ICP0 disrupts silencing in epithelial cells during lytic infection include degradation of cellular IFI16, degradation of PML and disruption of PML bodies, and disruption of the repressive HDAC-CoREST-LSD1-REST complex by dissociating HDAC (12, 14, 62). These targets operate within complex pathways that may also exhibit cell type-specific activity, and novel mechanisms might additionally be operational in neurons. For instance, CoREST is known to function in a variety of complexes involved in tissue-specific silencing, such as the mSin3 complex which can be repressive or activating for dynamic promoter regulation, the repressive NRD complex, and a third HDAC1/2-containing complex lacking REST and RbAp46/48 components (63). Therefore, ICP0 may interact with chromatin-modifying complexes uniquely expressed or functionally specialized in neuronal cells to promote heterochromatin formation during latent infection. A screen for such host factors in neurons could provide additional information about the mechanisms of the apparent dual roles for ICP0 in the lytic-latent balance.

Role for ICP0 in establishment and/or maintenance of latent infection. The effect of ICP0 on latent infection could be exerted during establishment of latent infection or maintenance of latent infection, or both, through several mechanisms. The establishment of latent infection occurs gradually within neurons during and after the resolution of acute infection. Previous studies have shown that heterochromatin accumulates progressively as latent infection is established (15, 16). First, early expression of ICP0 may facilitate establishment of latent infection by increasing viral genome loads in the ganglia. Enhanced viral genome numbers, lytic gene expression, and/or ICP0 levels may provoke a cellular immune response leading to enhanced silencing. Low levels of lytic gene expression during latency have been correlated with changes in neuronal gene expression (18, 64, 65). This suggests that HSV-1 may actively modulate the cellular environment to facilitate latency. ICP0 may help maintain a low level of lytic gene expression, whereas viruses lacking ICP0 may be cleared after encountering a hostile neuronal environment refractory to the establishment of latency. Future characterization of chromatin-modifying complexes that interact with ICP0 in neuronal cells during establishment of latency could indicate how ICP0 functions to recruit silencing complexes in neurons.

Previous molecular studies have demonstrated that ICP0 transcripts are expressed during latent infection (20, 39, 40) and that the ICP0 promoter was active during establishment and/or maintenance of latent infection in a fraction of latently infected neurons (41). However, there has been little evidence that ICP0 protein is expressed or that it is functioning in neurons. Our analysis of an ICP0 nonsense mutant virus provides strong genetic evidence that ICP0 protein is indeed expressed in neurons and has a function in promoting transcription and affecting latent viral chromatin.

ICP0 as a target for antivirals affecting latent infection. Our results argue for a role for ICP0 in promoting latent transcription and viral heterochromatin levels and raise the possibility that ICP0 might serve as a target for antivirals directed toward latent infection. A small-molecule inhibitor of ICP0 could reduce acute infection, establishment of latent infection, or reactivation from latent infection. Because all of the current HSV antivirals target other lytic infection targets such as the viral thymidine kinase and DNA polymerase, this report suggests an important new target for HSV drugs. In addition, small-molecule inhibitors could provide important research tools to probe the roles of ICP0 in establishment of latent infection versus maintenance. For example, administration of the inhibitors to mice during acute infection but after HSV has reached the sensory ganglia could test the role of ICP0 in establishment of latent infection. In contrast, administration of the inhibitors after latent infection has been established could test the role of ICP0 in maintenance of latent infection.
could be tested in the mouse, rabbit, and guinea pig infection models as done with drugs affecting enzymes that modify chromatin (32).

Inasmuch as LAT expression and heterochromatin modifications promote latency, results from ICP0 studies represent, to our knowledge, the first genetic evidence that a herpesviral protein functions to promote both lytic and latent infection. A number of herpesviral lytic proteins are reported to be expressed during latent infection (1), but there is limited information about their functions. Human cytomegalovirus UL84 and UL44 proteins function during lytic infection and are reported to interact with the latent viral genome (66), but their latent function(s) has not been defined. Accordingly, the identification of small-molecule inhibitors that inhibit ICP0 may provide new latent infection therapeutics for HSV. The elucidation of other viral proteins that promote latent infection of other herpesviruses should greatly expand the kinds of therapeutics that we have for this medically important group of viruses.

MATERIALS AND METHODS

Cells and viruses. U2OS (ATCC htb-96; ATCC, Manassas, VA) cells were maintained in Dulbecco’s modified essential medium (DMEM) supplemented with 5% (vol/vol) fetal calf serum, 5% (vol/vol) bovine calf serum, and 2 mM l-glutamine at 37°C. The HSV-1 n212 ICP0 nonsense mutant virus, which contains a nonsense mutation in codon 212, has been described previously (44). The n212R ICP0+ rescued virus was constructed by homologous recombination of a full-length ICP0-containing plasmid with infectious n212 virus (6). The dPROM ICP0-promoter deletion mutant virus and the corresponding PromR ICP0+ rescued virus were constructed by homologous recombination with the ICP0-null 7134 virus (6). Stocks of ICP0− and ICP0+ viruses were propagated and titrated in U2OS cells.

Mouse infections and isolation of trigeminal ganglia. Mice were housed in accordance with institutional and NIH guidelines on the care and use of animals in research, and all procedures were approved by the Institutional Animal Care and Use Committee of Harvard Medical School. Six-week-old CD1 male mice (Charles River Laboratories) were anesthetized in an isoflurane chamber followed by intraperitoneal injections of ketamine (3.7 mg/mouse) and xylazine hydrochloride (0.5 mg/mouse). The corneas were scarified, and infections were carried out at a dose of 2 × 10^6 PFU/eye of ICP0− viruses, PromR and n212R, and 2 × 10^6 PFU/eye of ICP0+ viruses, dPROM and n212. These doses were chosen because they yielded equivalent levels of replication in the eye in the first 2 to 3 dpi. To measure infection in the eye, swabs of tear film were collected using sterile polyester applicators (Puritan) for the first 5 dpi, and virus in the tear films from the eye was titrated on U2OS cells as described previously (67). Survival was measured for 28 days, and the resulting data were analyzed using GraphPad Prism software. At 28 dpi, the animals were sacrificed and the latently infected trigeminal ganglia were dissected and immediately frozen in liquid nitrogen and stored at −80°C.

ChIP. Chromatin immunoprecipitation (ChIP) analyses of TG were carried out as described previously (25) but with the following modifications. Intact TG were fixed at 37°C for 15 min in 20 ml of serum-free media containing 1% formaldehyde (16% formaldehyde ampules; Thermo Scientific). TG were then homogenized with Qiagen 5-mm-diameter stainless steel beads in a Qiagen TissueLyser LT 3 times at 50 oscillations per s for 2 min each time with a brief spin between steps. The homogenized samples were then sonicated at 4°C for about 9 cycles of 5 min each in a Diagenode Bioruptor on the high setting (15 s on, 45 s off) to shear the DNA to ~500-bp lengths. Immunoprecipitation reactions were carried out as described previously with 50 to 300 ng input DNA isolated. Immunoprecipitation reactions were carried out as described previously with 50 to 300 ng input DNA isolated. Immunoprecipitation reactions were carried out as described previously with 50 to 300 ng input DNA isolated.
REFERENCES

1. Pellett P, Roizman B. 2013. Herpesviridae, p 1802–1823. In Knipe DM, Howley PM, Cohen JJ, Griffin DE, Lamb RA, Martin MA, Raanizciel VR, Roizman B (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.

2. Roizman B, Knipe DM, Whitley RJ. 2013. Herpes simplex viruses, p 1823–1897. In Knipe DM, Howley PM, Cohen JJ, Griffin DE, Lamb RA, Martin MA, Raanizciel VR, Roizman B (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.

3. Knipe DM, Lieberman PM, Jung JU, McBride AA, Morris KV, Ott M, Margolis D, Nieto A, Nevels M, Parks RJ, Kristie TM. 2013. Snapshots: chromatin control of viral infection. Virology 435:141–156. http://dx.doi.org/10.1016/j.virol.2012.09.023.

4. Oh J, Fraser NW. 2008. Temporal association of the herpes simplex virus genome with histone proteins during a lytic infection. J Virol 82:3530–3537. http://dx.doi.org/10.1128/JVI.00856-07.

5. Cliffe AR, Knipe DM. 2008. Herpes simplex virus ICP0 promotes both histone removal and acetylation on viral DNA during lytic infection. J Virol 82:12300–12308. http://dx.doi.org/10.1128/JVI.01575-08.

6. Lee JS, Raja P, Knipe DM. 2016. Herpesviral ICP0 protein promotes two waves of heterochromatin removal on an early viral promoter during lytic infection. mBio 7:e02007-15. http://dx.doi.org/10.1128/mBio.02007-15.

7. Herrera PJ, Trienzenberg SJ. 2004. VP16-dependent associations of histone-modifying coactivators and underrepresentation of histones at immediate-early gene promoters during herpes simplex virus infection. J Virol 78:9689–9696. http://dx.doi.org/10.1128/JVI.78.18.9689-9696.2004.

8. Maull GG, Guldner HH, Spivack JG. 1993. Modulation of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0). J Gen Virol 74:2679–2690. http://dx.doi.org/10.1099/0092-2112-74-12-2679.

9. Glass M, Everett RD. 2013. Components of promyelocytic leukemia nuclear bodies (ND10) act cooperatively to repress herpesvirus infection. J Virol 87:2174–2185. http://dx.doi.org/10.1128/JVI.02950-12.

10. Jurak I, Silverstein LB, Sharma M, Coen DM. 2012. Herpes simplex virus is equipped with RNA- and protein-based mechanisms to repress expression of an ATRX, an effector of intrinsic immunity. J Virol 86:10993–10102. http://dx.doi.org/10.1128/JVI.01930-12.

11. Lukashchuk V, Everett RD. 2010. Regulation of ICP0-null mutant herpes simplex virus type 1 infection by ND10 components ATRX and dHax. J Virol 84:4026–4040. http://dx.doi.org/10.1128/JVI.02597-09.

12. Gu H, Liang Y, Mandel G, Roizman B. 2005. Components of the REST/COREST/histone deacetylase repressor complex are disrupted, modified, and translocated in HSV-1-infected cells. Proc Natl Acad Sci U S A 102:7571–7576. http://dx.doi.org/10.1073/pnas.0502658102.

13. Kalamvoki M, Roizman B. 2011. The histone acetyltransferase CLOCK is an essential component of the herpes simplex virus 1 transcriptional program. J Virol 85:9472–9477. http://dx.doi.org/10.1128/JVI.00876-11.

14. Orzalli MH, DeLuca NA, Knipe DM. 2012. Nuclear ICP16 induction of IFR-3 signaling during herpesviral infection and degradation of IFR16 by the viral ICP0 protein. Proc Natl Acad Sci U S A 109:E3008–E3017. http://dx.doi.org/10.1073/pnas.1211302109.

15. Cliffe AR, Coen DM, Knipe DM. 2013. Kinetics of facultative heterochromatin and polycomb group protein association with the herpes simplex viral genome during establishment of latent infection. mBio 4:e00590-12. http://dx.doi.org/10.1128/mBio.00590-12.

16. Wang Q-Y, Zhou C, Johnson KE, Colgrove RG, Coen DM, Knipe DM. 2005. Herpesviral latency-associated transcript gene promotes assembly of heterochromatin on viral lytic-genie promoters in latent infection. Proc Natl Acad Sci U S A 102:16035–16059. http://dx.doi.org/10.1073/pnas.0505850102.

17. Kramer MF, Coen DM. 1995. Quantification of transcripts from the ICP4 and thymidine kinase genes in mouse ganglia latently infected with herpes simplex virus. J Virol 69:1389–1399.

18. Ma JZ, Russell TA, Spelman T, Carbone FR, Tschanke DC. 2014. Lytic gene expression is frequent in HSV-1 latent infection and correlates with the engagement of a cell-intrinsic transcriptional response. PLoS Pathog 10:e1004237. http://dx.doi.org/10.1371/journal.ppat.1004237.

19. Kramer MF, Jurak I, Pesola JM, Boisell S, Knipe DM, Coen DM. 2011. Herpesvirus ICP0 primes microRNAs expressed abundantly during latent infection are not essential for latency in mouse trigeminal ganglia. Virol 417:239–247. http://dx.doi.org/10.1016/j.virol.2011.06.027.

20. Pesola JM, Zha J, Knipe DM, Coen DM. 2005. Herpes simplex virus immediate-early and early gene expression during reactivation from latency under conditions that prevent infectious virus production. J Virol 79:14516–14525. http://dx.doi.org/10.1128/JVI.79.23.14516-14525.2005.

21. Stevens JG, Wagner EK, Devi-Rao GB, Cook ML, Feldman LT. 1987. RNA complementary to herpesvirus alpha gene mRNA is prominent in latent infected neurons. Science 235:1056–1059. http://dx.doi.org/10.1126/science.2434993.

22. Deatly AM, Spivack JG, Lavi E, Fraser NW. 1987. RNA from an immediate early region of the type 1 herpes simplex virus genome is present in the trigeminal ganglia of latently infected mice. Proc Natl Acad Sci U S A 84:3204–3208. http://dx.doi.org/10.1073/pnas.84.10.3204.

23. Umbach JL, Kramer MF, Jurak I, Karnowski HW, Coen DM, Cullen BR. 2008. MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature 454:780–783. http://dx.doi.org/10.1038/nature07103.

24. Deshmule SL, Fraser NW. 1989. During latency, herpes simplex virus type 1 DNA is associated with nucleosomes in a chromatin structure. J Virol 63:943–947.

25. Cliffe AR, Garber DA, Knipe DM. 2009. Transmission of the herpes simplex virus latency-associated transcript promotes the formation of facultative heterochromatin on lytic promoters. J Virol 83:8112–8190. http://dx.doi.org/10.1128/JVI.00712-09.

26. Kwiatkowski DL, Thompson HW, Bloom DC. 2009. The polycomb group protein Bmi1 binds to the herpes simplex virus 1 latent genome and maintains repressive histone marks during latency. J Virol 83:8173–8181. http://dx.doi.org/10.1128/JVI.00686-09.

27. Kubat NJ, Amelio AL, Giordani NV, Bloom DC. 2004. The herpes simplex virus type 1 latency-associated transcript (LAT) enhancer/rcr is hyperacetylated during latency independently of LAT transcription. J Virol 78:12508–12518. http://dx.doi.org/10.1128/JVI.78.22.12508-12518.2004.

28. Da Silva LF, Jones C. 2013. Small non-coding RNAs encoded within the herpes simplex virus type 1 latency associated transcript (LAT) cooperate with the retinoic acid inducible gene I (RIG-I) to induce beta interferon promoter activity and promote cell survival. Virus Res 175:101–109. http://dx.doi.org/10.1016/j.virusres.2013.04.005.

29. Thompson RL, Sawtell NM. 2001. Herpes simplex virus type 1 latency-associated transcript gene promotes neuronal survival. J Virol 75:6660–6675. http://dx.doi.org/10.1128/JVI.75.14.6660-6675.2001.

30. Chen SH, Kramer MF, Schaffer PA, Coen DM. 1997. A viral function represses accumulation of transcripts from productive-cycle genes in mouse ganglia latently infected with herpes simplex virus. J Virol 71:5878–5884.

31. Garber DA, Schaffer PA, Knipe DM. 1997. A LAT-associated function reduces productive-cycle gene expression during acute infection of murine sensory neurons with herpes simplex virus type 1. J Virol 71:5885–5893.

32. Hill JM, Quenelle DC, Cardin RD, Vogel JL, Clement C, Bravo FJ, ...
Foster TP, Bosch-Marce M, Raja P, Lee JS, Bernstein DI, Krause PR, Knipe DM, Kristie TM. 2014. Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes. Sci Transl Med 6:263ra169. http://dx.doi.org/10.1126/scitranslmed.3010643.

Pan D, Flores O, Umbach JL, Pesoja JM, Bentley P, Rosato PC, Leib DA, Cullen BR, Coen DM. 2014. A neuron-specific host microRNA targets herpes simplex virus-1 ICP0 expression and promotes latency. Cell Host Microbe 15:446–456. http://dx.doi.org/10.1016/j.chom.2014.03.004.

Sacks WR, Schaffer PA. 1987. Deletion mutants in the gene encoding the herpes simplex virus type 1 immediate-early protein ICP0 exhibit impaired growth in cell culture. J Virol 61:829–839.

Cai W, Schaffer PA. 1992. Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early, and late genes in productively infected cells. J Virol 66:2904–2915.

Cai W, Astor TL, Liptak LM, Cho C, Coen DM, Schaffer PA. 1993. The herpes simplex virus type 1 regulatory protein ICP0 enhances virus replication during acute infection and reactivation from latency. J Virol 67:7501–7512.

Leib DA, Coen DM, Bogard CL, Hicks KA, Yager DR, Knipe DM, Tyler KL, Schaffer PA. 1989. Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J Virol 63:759–768.

Halford WP, Schaffer PA. 2001. ICP0 is required for efficient reactivation of herpes simplex virus type 1 from neuronal latency. J Virol 75:3240–3249. http://dx.doi.org/10.1128/JVI.75.7.3240-3249.2001.

Chen S-H, Lee LY, Garber DA, Schaffer PA, Knipe DM, Coen DM. 2002. Neither LAT nor open reading frame P mutations increase expression of spliced or intron-containing ICP0 transcripts in mouse ganglia latently infected with herpes simplex virus. J Virol 76:4764–4772. http://dx.doi.org/10.1128/JVI.76.7.4764-4772.2002.

Maillot S, Naas T, Crepin S, Roque-Afonso AM, Lafay F, Efstathiou S, Labetouille M. 2006. Herpes simplex virus type 1 latently infected neurons differentially express latency-associated and ICP0 transcripts. J Virol 80:9310–9321. http://dx.doi.org/10.1128/JVI.02615-05.

Proença JT, Coleman HM, Connor V, Winton DJ, Efstathiou S. 2008. A historical analysis of herpes simplex virus promoter activation in vivo reveals distinct populations of latently infected neurons. J Gen Virol 89:2965–2974. http://dx.doi.org/10.1099/vir.0.006506-0.

Speck PG, Simmons A. 1991. Divergent molecular pathways of productive and latent infection with a virulent strain of herpes simplex virus type 1. J Virol 65:4001–4005.

Wilcox CL, Smith RL, Everett RD, Myśliński D. 1997. The herpes simplex virus type 1 immediate-early protein ICP0 is necessary for the efficient establishment of latent infection. J Virol 71:5677–5685.

Cai WZ, Schaffer PA. 1989. Herpes simplex virus type 1 ICP0 plays a critical role in the de novo synthesis of infectious virus following transfection of viral DNA. J Virol 63:4579–4589.

Halford WP, Schaffer PA. 2000. Optimized viral dose and transient immunosuppression enable herpes simplex virus ICP0-null mutants to establish wild-type levels of latency in vivo. J Virol 74:5957–5967. http://dx.doi.org/10.1128/JVI.74.11.5957-5967.2000.

Yao F, Schaffer PA. 1995. An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1. J Virol 69:6249–6258.

Giresi PG, Kim J, McDaniell RM, Iyer VR, Lieb JD. 2007. FAIRE (formaldehyde-assisted isolation of regulatory elements) isolates active regulatory elements from human chromatin. Genome Res 17:877–885. http://dx.doi.org/10.1101/gr.533506.107.

Proença JT, Coleman HM, Nicoll MP, Connor V, Preston CM, Arthur C, Efstathiou S. 2011. An investigation of herpes simplex virus promoter activity compatible with latency establishment reveals VP16-independent activation of immediate-early promoters in sensory neurons. J Gen Virol 92:2575–2583. http://dx.doi.org/10.1099/vir.0.034728-0.

Gelman IH, Silverstein S. 1985. Identification of immediate early genes from herpes simplex virus that transactivate the virus thymidine kinase gene. Proc Natl Acad Sci USA 82:5265–5269. http://dx.doi.org/10.1073/pnas.82.16.5265.

O’Hare P, Hayward GS. 1985. Evidence for a direct role for both the 175,000- and 110,000-molecular-weight immediate-early proteins of herpes simplex virus in the transactivation of delayed-early promoters. J Virol 53:751–760.

Everett RD. 1985. Activation of cellular promoters during herpes virus infection of biochemically transformed cells. EMBO J 4:1973–1980.

Hobbs WE, DeLuca NA. 1999. Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. J Virol 73:8245–8255.

Frazier DP, Cox D, Godõlch EM, Schaffer PA. 1996. The herpes simplex virus type 1 latency-associated transcript promoter is activated through Ras and Raf by nerve growth factor and sodium butyrate in PC12 cells. J Virol 70:7424–7432.

Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL, Lander ES. 2006. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125:315–326. http://dx.doi.org/10.1016/j.cell.2006.02.041.

Greer EL, Shi Y. 2012. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 13:345–357. http://dx.doi.org/10.1038/nrg3173.

Catez F, Picard C, Held K, Gross S, Rousseau A, Theil D, Sawtell N, Labetouille M, Lomonte P. 2012. HSV-1 genome subnuclear positioning and associations with host-cell PML-NBs and centromeres regulates LAT locus transcription during latency in neurons. PLoS Pathog 8:e1002852. http://dx.doi.org/10.1371/journal.ppat.1002852.

Oh HS, Bryant NF, Nieland TJ, Mazumder A, Bagul M, Bathe M, Root DE, Knipe DM. 2014. A targeted RNA interference screen reveals novel epigenetic factors that regulate herpessviral gene expression. mBio 5:e01086-13. http://dx.doi.org/10.1128/mBio.01086-13.

Everett RD, Freemont P, Saitoh H, Dasso M, Kathoria M, Cohen P, Parkinson J. 1998. The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J Virol 72:5681–5691.

You A, Tong JK, Grozinger CM, Schreiber SL. 2001. CoREST is an integral component of the CoREST-human histone deacetylase complex. Proc Natl Acad Sci USA 98:1454–1458. http://dx.doi.org/10.1073/pnas.98.4.1454.

Kramer MF, Cook WJ, Roth FP, Zhu J, Holman H, Knipe DM, Coen DM. 2003. Latent herpes simplex virus infection of sensory neurons alters neuronal gene expression. J Virol 77:9533–9541. http://dx.doi.org/10.1128/JVI.77.17.9533-9541.2003.

Chen S-H, Garber DA, Schaffer PA, Knipe DM, Coen DM. 2000. Persistent expression of latency-associated early promoters in ganglia latently infected with herpes simplex virus in the absence of viral replication and reactivation. Virology 278:207–216. http://dx.doi.org/10.1006/viro.2000.0643.

Rossetto CC, Tarrant-Elorza M, Pari GS. 2013. Cis and trans acting factors involved in human cytomegalovirus experimental and natural latent infection of CD14(+) monocytes and CD34(+) cells. PLoS Pathog 9:e1003366. http://dx.doi.org/10.1371/journal.ppat.1003366.

Coen DM, Kosz-Vencek M, Jacobson JG, Leib DA, Bogard CL, Schaffer PA, Tyler KL, Knipe DM. 1989. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci U S A 86:4736–4740. http://dx.doi.org/10.1073/pnas.86.12.4736.

Orzalli MH, Conway SE, Berrios C, Decaprio JA, Knipe DM. 2013. Nuclear interferon-inducible protein 16 promotes silencing of herpesviral and transfected DNA. Proc Natl Acad Sci U S A 110:E4492–E4501. http://dx.doi.org/10.1073/pnas.1316194110.